Noxopharm Limited
https://www.noxopharm.com/site/content/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Noxopharm Limited
Biopharma Quarterly Dealmaking Statistics, Q3 2016
In Q3, biopharma financing totaled $7.4 billion, a large proportion of which was by rare disease developers; among the highlights in the $23 billion in M&As was Allergan's buying spree, including two NASH companies. Just over $20 billion went into biopharma alliance dealmaking, and neurology assets attracted many of the dollars.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Other Names / Subsidiaries
-
- Nyrada, Inc., Pharmorage Pty Ltd
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice